About mediwound ltd - MDWD
MediWound Ltd. is a biopharmaceutical company, which engages in the development, manufacture, and commercialization of products to address needs in the fields of severe burns, chronic wounds, and other hard-to-heal wounds. Its product NexoBrid, is an orphan biologic for eschar removal in severe burns. The company was founded by Lior Rosenberg and Marian Gorecki in January 2000 and is headquartered in Yavne, Israel.
MDWD At a Glance
MediWound Ltd.
42 Hayarkon Street
Yavne, HaMerkaz 8122745
| Phone | 972-77-971-4100 | Revenue | 16.96M | |
| Industry | Pharmaceuticals: Major | Net Income | -23,879,000.00 | |
| Sector | Health Technology | Employees | 121 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MDWD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.383 |
| Price to Book Ratio | 5.43 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -7.028 |
| Enterprise Value to Sales | 9.767 |
| Total Debt to Enterprise Value | 0.053 |
MDWD Efficiency
| Revenue/Employee | 140,157.025 |
| Income Per Employee | -197,347.107 |
| Receivables Turnover | 7.15 |
| Total Asset Turnover | 0.212 |
MDWD Liquidity
| Current Ratio | 2.333 |
| Quick Ratio | 2.173 |
| Cash Ratio | 2.067 |
MDWD Profitability
| Gross Margin | 12.589 |
| Operating Margin | -149.059 |
| Pretax Margin | -139.808 |
| Net Margin | -140.804 |
| Return on Assets | -29.895 |
| Return on Equity | -63.86 |
| Return on Total Capital | -45.565 |
| Return on Invested Capital | -53.391 |
MDWD Capital Structure
| Total Debt to Total Equity | 20.111 |
| Total Debt to Total Capital | 16.744 |
| Total Debt to Total Assets | 10.173 |
| Long-Term Debt to Equity | 18.684 |
| Long-Term Debt to Total Capital | 15.555 |